EUVIMEDEUVIMED entdecken
Open Access

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies

Zhen Lu iD, Ioannis Verginadis iD, Motofumi Kumazoe iD, Gerardo M Castillo iD, Yao Yao iD, Rebecca E Guerra iD, Sandra Bicher iD, Menghao You iD, George McClung iD, Rong Qiu iD, Zebin Xiao iD, Zhen Miao iD und 20 weitere

Science Translational Medicine · 21.08.2024 · 16 (761)

DOI: 10.1126/scitranslmed.adn0904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 21.08.2024. Verfasst von Zhen Lu und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Neovascularization, Pathologic, Natriuretic Peptide, C-Type, Tumor Microenvironment. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deficit of oxygen and nutrients in the tumor microenvironment (TME) triggers abnormal angiogenesis that produces dysfunctional and leaky blood vessels, which fail to adequately perfuse tumor tissues. Resulting hypoxia, exacerbation of metabolic disturbances, and generation of an immunosuppressive TME undermine the efficacy of anticancer therapies. Use of carefully scheduled angiogenesis inhibitors has been suggested to overcome these problems and normalize the TME. Here, we propose an alternative agonist-based normalization approach using a derivative of the C-type natriuretic peptide (dCNP). Multiple gene expression signatures in tumor tissues were affected in mice treated with dCNP. In several mouse orthotopic and subcutaneous solid tumor models including colon and pancreatic adenocarcinomas, this well-tolerated agent stimulated formation of highly functional tumor blood vessels to reduce hypoxia. Administration of dCNP also inhibited stromagenesis and remodeling of the extracellular matrix and decreased tumor interstitial fluid pressure. In addition, treatment with dCNP reinvigorated the antitumor immune responses. Administration of dCNP decelerated growth of primary mouse tumors and suppressed their metastases. Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in immunocompetent mice. These results demonstrate the proof of principle for using vasculature normalizing agonists to improve therapies against solid tumors and characterize dCNP as the first in class among such agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neovascularization, PathologicNatriuretic Peptide, C-TypeTumor MicroenvironmentAnimalsMiceHumansCell Line, TumorNeoplasmsImmunity

Substanzen

Natriuretic Peptide, C-Type

Autor:innen und Institutionen

  • Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 819-0395, Japan.
  • PharmaIN Corp., Bothell, WA 98011, USA.
  • Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Zhen Lu, Ioannis Verginadis, Motofumi Kumazoe, Gerardo M Castillo, Yao Yao, Rebecca E Guerra, Sandra Bicher, Menghao You, George McClung, Rong Qiu, Zebin Xiao, Zhen Miao, Subin S George, Daniel P Beiting, Takashi Nojiri, Yasutake Tanaka, Akiko Nishimoto-Ashfield, Wei Guo, Yi Fan, J Alan Diehl, Ben Z Stanger, Terence P Gade, Ellen Puré, Constantinos Koumenis, Elijah M Bolotin, Serge Y Fuchs

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS

Zitieren

APA

Lu, Z., Verginadis, I., Kumazoe, M., Castillo, G. M., Yao, Y., Guerra, R. E., Bicher, S., You, M., McClung, G., Qiu, R., Xiao, Z., Miao, Z., George, S. S., Beiting, D. P., Nojiri, T., Tanaka, Y., Fujimura, Y., Onda, H., Hatakeyama, Y., …, & Fuchs, S. Y. (2024). Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Science Translational Medicine, 16(761). https://doi.org/10.1126/scitranslmed.adn0904

Vancouver

Lu Z, Verginadis I, Kumazoe M, Castillo GM, Yao Y, Guerra RE, et al. Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Science Translational Medicine. 2024;16(761). doi:10.1126/scitranslmed.adn0904

BibTeX
@article{Lu2024,
  author = {Lu, Zhen and Verginadis, Ioannis and Kumazoe, Motofumi and Castillo, Gerardo M and Yao, Yao and Guerra, Rebecca E and Bicher, Sandra and You, Menghao and McClung, George and Qiu, Rong and Xiao, Zebin and Miao, Zhen and George, Subin S and Beiting, Daniel P and Nojiri, Takashi and Tanaka, Yasutake and Fujimura, Yoshinori and Onda, Hiroaki and Hatakeyama, Yui and Nishimoto-Ashfield, Akiko and Bykova, Katrina and Guo, Wei and Fan, Yi and Buynov, Nikolay M and Diehl, J Alan and Stanger, Ben Z and Tachibana, Hirofumi and Gade, Terence P and Puré, Ellen and Koumenis, Constantinos and Bolotin, Elijah M and Fuchs, Serge Y},
  title = {Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {761},
  doi = {10.1126/scitranslmed.adn0904}
}
Kostenlos starten →